Jinlong Wei1,2,3, Jie Wu1,2,3, Huanhuan Wang1,2,3, Bin Wang1,2,3, Tingting Zhao1,2,3, Lingbin Meng4, Lihua Dong1,2,3, Xin Jiang1,2,3. 1. Department of Radiation Oncology, The First Hospital, Jilin University, Changchun, China. 2. Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. 3. NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. 4. Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Abstract
BACKGROUND: Episil® is a bioadhesive barrier-forming oral liquid gel that can relieve oral mucositis (OM) caused by radiotherapy (RT) and hence relieves pain effectively. In this study, we observed the effects of Episil® on the OM and nutritional status of patients with head and neck cancers (HNCs) undergoing RT. METHODS: A total of 50 HNC patients were divided into the Episil® (25 patients) and control (25 patients) groups. Patients in the Episil® group were sprayed with Episil®. In the control group, the kangfuxin solution or Kangsu™ oral gargle was used. Medical staff assessed the OM extent and timing as well as the nutritional status during treatment and recorded adverse reactions other than OM. The nutritional status assessment included the following indicators: Patient Generated-Subjective Global Assessment (PG-SGA) score, body mass index (BMI), body weight, albumin levels, and other hematological indicators. RESULTS: The incidence of high-level OM (III-IV) after RT was lower in the Episil® group than in the control group (P < 0.05). Nutritional status assessments showed that the Episil® group had a lower percentage of weight loss than the control group at weeks 4 and 7 after RT. Similar results were also obtained for BMI and albumin levels (P < 0.05). Moreover, according to PG-SGA scores, fewer patients in the Episil® group were malnourished and more patients were well-nourished (P < 0.05) compared with the control group. CONCLUSION: Episil® effectively improved OM and malnutrition in HNC patients who received RT and has a good clinical application value.
BACKGROUND: Episil® is a bioadhesive barrier-forming oral liquid gel that can relieve oral mucositis (OM) caused by radiotherapy (RT) and hence relieves pain effectively. In this study, we observed the effects of Episil® on the OM and nutritional status of patients with head and neck cancers (HNCs) undergoing RT. METHODS: A total of 50 HNC patients were divided into the Episil® (25 patients) and control (25 patients) groups. Patients in the Episil® group were sprayed with Episil®. In the control group, the kangfuxin solution or Kangsu™ oral gargle was used. Medical staff assessed the OM extent and timing as well as the nutritional status during treatment and recorded adverse reactions other than OM. The nutritional status assessment included the following indicators: Patient Generated-Subjective Global Assessment (PG-SGA) score, body mass index (BMI), body weight, albumin levels, and other hematological indicators. RESULTS: The incidence of high-level OM (III-IV) after RT was lower in the Episil® group than in the control group (P < 0.05). Nutritional status assessments showed that the Episil® group had a lower percentage of weight loss than the control group at weeks 4 and 7 after RT. Similar results were also obtained for BMI and albumin levels (P < 0.05). Moreover, according to PG-SGA scores, fewer patients in the Episil® group were malnourished and more patients were well-nourished (P < 0.05) compared with the control group. CONCLUSION: Episil® effectively improved OM and malnutrition in HNC patients who received RT and has a good clinical application value.
Authors: Alison M Rose-Ped; Lisa A Bellm; Joel B Epstein; Andy Trotti; Clement Gwede; Henry J Fuchs Journal: Cancer Nurs Date: 2002-12 Impact factor: 2.592
Authors: Jann Arends; Patrick Bachmann; Vickie Baracos; Nicole Barthelemy; Hartmut Bertz; Federico Bozzetti; Ken Fearon; Elisabeth Hütterer; Elizabeth Isenring; Stein Kaasa; Zeljko Krznaric; Barry Laird; Maria Larsson; Alessandro Laviano; Stefan Mühlebach; Maurizio Muscaritoli; Line Oldervoll; Paula Ravasco; Tora Solheim; Florian Strasser; Marian de van der Schueren; Jean-Charles Preiser Journal: Clin Nutr Date: 2016-08-06 Impact factor: 7.324
Authors: Alfonso Vidal-Casariego; Alicia Calleja-Fernández; María D Ballesteros-Pomar; Isidoro Cano-Rodríguez Journal: Nutr Cancer Date: 2013 Impact factor: 2.900
Authors: Yuan Cheng; Shu Kui Qin; Yan Ping Chen; Li Hua Dong; Xiang Dong Sun; Shi Ying Yu; Shi Kai Wu Journal: Onco Targets Ther Date: 2018-11-30 Impact factor: 4.147
Authors: Sali Al-Ansari; Judith A E M Zecha; Andrei Barasch; Jan de Lange; Fred R Rozema; Judith E Raber-Durlacher Journal: Curr Oral Health Rep Date: 2015-10-19